Journal
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 129, Issue 2, Pages 252-262Publisher
AMER SOC CLINICAL PATHOLOGY
DOI: 10.1309/CCR3QN4874YJDJJ7
Keywords
esophagus; residual carcinoma; neoadjuvant chemoradiotherapy; tumor regression grading; histopathology
Categories
Ask authors/readers for more resources
Neoadjuvant chemoradiotherapy is being increasingly offered to patients with invasive esophageal carcinoma in an effort to downstage the tumor and consequently increase the rate of curative resection. A substantial amount of data has suggested that pathologic tumor regression following neoadjuvant therapy is an important predictor of local recurrence and long-term survival in esophageal cancer Therefore, it is important that these posttreatment resection specimens are handled in a standardized manner and a reproducible method of tumor regression grading is used. Pathologic examination of such specimens is not straightforward, and, in fact, it presents a particular challenge to pathologists, especially when a good response to neoadjuvant therapy has been achieved and little or no residual tumor remains. We provide some guidelines for handling and reporting such specimens and outline the commonly used tumor regression grading systems for posttreatment esophagectomy specimens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available